Lanadelumab Added to NS Formulary

2021-09-13T15:48:46-06:00

Lanadelumab (TAKHZYRO), a treatment to routinely prevent attacks in patients with HAE Type I or II who are 12 years old and up, was recently added to Nova Scotia's drug formulary. To access this treatment,